From The American Journal of Managed Care, “On the Horizon for Multiple Myeloma”

This article—written by Michael Marlan Mohundro, PharmD, and Brice Labruzzo Mohundro, PharmD—highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials. The new regimens discussed include proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors.

See the article, “On the Horizon for Multiple Myeloma,” from The American Journal of Managed Care in its entirety here.